Australian Clinical Labs is a diagnostics & research business based in Australia. Australian Clinical Labs shares (ACL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Australian Clinical Labs has a trailing 12-month revenue of around $674 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Australian Clinical Labs, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $2.2351 - $3.6013 |
|---|---|
| 50-day moving average | $2.661 |
| 200-day moving average | $2.8345 |
| Target price | $3.03 |
| PE ratio | 30.125 |
| Dividend yield | $0.1 (4.15%) |
| Earnings per share (TTM) | $0.08 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$2.41
| 1 week (2024-04-16) | -0.82% |
|---|---|
| 1 month (2024-03-22) | -9.40% |
| 3 months (2024-01-24) | -20.72% |
| 6 months (2023-10-24) | -14.23% |
| 1 year (2023-04-24) | -33.97% |
|---|---|
| 2 years (2022-04-22) | -53.65% |
Valuing Australian Clinical Labs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Australian Clinical Labs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Australian Clinical Labs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Australian Clinical Labs shares trade at around 30x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Australian Clinical Labs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $66.6 million (£0.0 million).
The EBITDA is a measure of a Australian Clinical Labs's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $674 million |
|---|---|
| Operating margin TTM | 6.95% |
| Gross profit TTM | $250.4 million |
| Return on assets TTM | 5.58% |
| Return on equity TTM | 9.19% |
| Profit margin | 2.29% |
| Book value | 0.822 |
| Market capitalisation | $486.4 million |
TTM: trailing 12 months
We're not expecting Australian Clinical Labs to pay a dividend over the next 12 months.
Over the last 12 months, Australian Clinical Labs's shares have ranged in value from as little as $2.2351 up to $3.6013. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Australian Clinical Labs's is 1.17. This would suggest that Australian Clinical Labs's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. Australian Clinical Labs Limited was incorporated in 2020 and is headquartered in Clayton, Australia.
AMP Ltd Preferred
AUD104.55
ANZ Group Holdings Ltd. Pfd.
AUD101.63
ANZ Group Holdings Ltd. Pfd.
AUD103.35
Macquarie Bank Ltd Pref
AUD106.27
Macquarie Group Ltd Pref C
AUD102.80
Macquarie Group Limited
AUD105.62
Suncorp Group Ltd Pref
AUD100.61
Westpac Banking Corp Pref
AUD102.76
Everything we know about the Sun Silver IPO, plus information on how to buy in.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.